Navigation Links
Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
Date:6/19/2012

RALEIGH, N.C., June 19, 2012 /PRNewswire-iReach/ -- Scioderm today announced results from its Phase II clinical trial investigating the efficacy, safety and tolerability of topical administration of SD-101, a dermal pharmaceutical in development for treatment of chronic wounds and lesions in children with various types of Epidermolysis Bullosa. The open label study was conducted in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB. Eight children with EB (Simplex, RDEB, or Junctional EB) were enrolled and received daily administration by their caregivers of topically applied SD-101 over their entire body for a period of up to 3 months. The primary outcome measures were assessment of target wound area reduction and closure, and reduction in BSA coverage of lesions and erosions.  In the Phase II trial, SD-101 application resulted in closure of 85% of target chronic lesions, in addition to a 55% reduction in BSA coverage of lesions and erosions. SD-101 was well tolerated by the children, with daily administration up to 3 months.

SD-101 has also been designated as an orphan drug by the U.S. Food and Drug Administration for the treatment of Epidermolysis Bullosa (EB). Orphan drug designation provides a number of benefits to the company, including seven years of market exclusivity once SD-101 receives FDA clearance, assistance from the FDA with guiding SD-101 through the regulatory approval process, and waiver or partial payment of application fees and tax credits for clinical testing expenses conducted after orphan designation is received.

Robert Ryan, Ph.D., Chief Executive Officer of Scioderm added, "Epidermolysis Bullosa is a devastating disease. Our results from this trial indicate that SD-101 is a product candidate for treatment of the lesions and blistering on skin in children with EB, who have no other treatment alternatives, and it appears to have a favorable safety profile. We believe these data support the use of
'/>"/>

SOURCE Scioderm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Canada-based Radimetrics Announces Expansion to Scotland
2. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
3. American Oriental Bioengineering Announces Appointment of Audit Committee Chairman
4. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
5. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
6. iBio Announces Important Expansion of its Intellectual Property Portfolio: Allowance of Patent for Anthrax Vaccines and Further Application of Modulator Platform
7. Zimmer Announces Quarterly Dividend for Second Quarter of 2012
8. American Oriental Bioengineering Announces Change of Independent Auditors
9. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
10. UltraTape announces Cleanroom Labels for Cryogenic Laboratory applications
11. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Based on ... market, Frost & Sullivan recognizes Ventana Medical Systems, ... with the 2014 North American Frost & Sullivan ... quality practices along with a focus on innovation ... global leader in tissue-based cancer diagnostic solutions for ...
(Date:9/30/2014)... YORK , Sept. 30, 2014  Proteomics ... according to a new report from Kalorama Information.  The ... deals had occurred in proteomics in the past ... IPOs, to agreements between private proteomic companies and ... companies with novel proteomics innovator companies.  Kalorama observed ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
(Date:9/30/2014)... HealthDay Reporter TUESDAY, Sept. 30, 2014 ... put the brakes on motherhood. And for many young women, ... new research suggests. Women in their early 20s appear ... tough economic times. But, according to the new study, that ... 40s and beyond. The findings suggest that higher unemployment ...
(Date:9/30/2014)... "brain tsunamis" in injured patients without opening the ... thanks to pioneering research at the University of ... led by Jed Hartings, PhD, research associate professor ... College of Medicine, has shown that spreading depolarizationselectrical ... tsunami wavescan be measured by the placement of ...
(Date:9/30/2014)... 2014 (HealthDay News) -- Sleep apnea is a potential health ... to a possible culprit behind the disorder: a "fat" tongue. ... deposits are increased in the tongue of obese patients with ... of the Sleep Center at the University of Pennsylvania Medical ... which will publish the findings Oct. 1. Sleep apnea ...
(Date:9/30/2014)... stranger to the children of Tanzania. What is rare ... services, including reliable diagnosis and evidence-based treatments. There is ... in Swahili, a major language of the region. In ... and the University of Georgia (UGA) describe a culturally ... in the country and found to be effective for ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
Breaking Medicine News(10 mins):Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 2Health News:Recessions May Thwart a Woman's Motherhood Plans Forever: Study 3Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2
... food products. According to a team of University of ... on its viewers, especially university students. , "The transition ... a time for taking on many negative health behaviors ... in physical activity and fruit and vegetable consumption," said ...
... common vaginal infection may make women more susceptible to contracting ... at Chapel Hill School of Public Health researchers have found. ... more than 30,700 women from around the world, showed that ... vaginosis in women of reproductive age were more likely ...
... standardization across ... savings, IRVINE, Calif., July 31 Masimo, ... that Aurora Health Care has completed a system-wide,conversion ... health,care provider with 13 hospitals and more than ...
... support nonprofits in Portland and Seattle that improve health ... ... 31 The Regence Foundation today,announced three grants totaling $195,000 for ... Regence,Foundation is the corporate foundation of The Regence Group and was ...
... and health systems,expert Ann Lion Coleman will join ... project in August 2008. Health Systems 20/20 is ... to strengthen health,systems by using an integrated approach ... to further the use of,life-saving priority health services., ...
... July 31 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Western,healthcare products and services in the People,s Republic ... its fiscal 2009 first quarter,financial results on Thursday, ... host a conference call at 8:00 am ET ...
Cached Medicine News:Health News:Watching too much TV is causing some university students to pack on the pounds 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 2Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 3Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 4Health News:Aurora Health Care Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology 5Health News:Regence Foundation Announces Three Grants Totaling $195,000 2Health News:Ann Lion Coleman Joins Abt Associates to Direct USAID Health Systems 20/20 Project 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 2Health News:Chindex International to Report Fiscal 2009 First Quarter Financial Results 3
... , Standby: A standby switch maintains power to ... 1 s (1 pulse/s) , Tetanus: 100 ... s) , Output Current: Adjustable from 0-70 mA ... (200-us duration) , Indicators: Battery LED (green) indicates ...
... A range of easy to use ... RDG nerve locator, peripheral nerve stimulator, and ... insulating pole, plastic hub, and pencil point ... an inexpensive, practical and easy to use ...
Based on the original MS-1 design the new MS-1B includes low battery detection, FET based output circuitry and enhanced battery compartment....
... for the delivery and monitoring of inhaled ... is a fully integrated, innovative instrument used ... therapy. The INOvent delivery system works in ... machine) to deliver a constant concentration of ...
Medicine Products: